

**Correction to
Lancet Oncol 2019;
20: 1286–94**

Calais J, Ceci F, Eiber M, et al. ¹⁸F-fluciclovine PET-CT and ⁶⁸Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. *Lancet Oncol* 2019; **20**: 1286–94—In this Article, in figure 2, the ¹⁸F-fluciclovine detection rate for prostate bed has been corrected to “9 (18%)”. This correction has been made to the online version as of Sept 23, 2019.

**Correction to
Lancet Oncol 2019;
20: 1602–14**

Oscarsson N, Müller B, Rosén A, et al. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2–3 trial. *Lancet Oncol* 2019; **20**: 1602–14—In the summary of this Article, the first sentence of the Findings section should have read “Of 223 patients screened between May 9, 2012, and Dec 20, 2017, 87 patients were enrolled and randomly assigned to either hyperbaric oxygen therapy (n=42) or standard care (n=45).” This correction has been made to the online version as of Sept 23, 2019, and the printed Article is correct.

**Correction to
Lancet Oncol 2019;
20: 1506–517**

Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol* 2019; **20**: 1506–517—In this Article, the name of the funder should be “ONO Pharmaceutical Company”, and in the Results section, paragraph eight, the data for the comparison between groups for the utility index should have been 0.076, 0.011–0.142; p=0.023. In addition, minor typographical errors have been corrected. This correction has been made to the online version as of Oct 30, 2019, and the printed Article is correct.

**Correction to
Lancet Oncol 2019;
20: e522–34**

Spence D, Argentieri MA, Andall-Brereton G, et al. Advancing cancer care and prevention in the Caribbean: a survey of strategies for the region. *Lancet Oncol* 2019; **20**: e522–34—In this Series paper, the value 55% was missing from the following sentence in the first paragraph of the Strategies for providing paediatric oncology services section: “Data from hospital-based registries in the English-speaking Caribbean islands show a 2-year survival rate of 55% compared with 85% in HICs.” This correction has been made to the online version as of Oct 30, 2019.

**Correction to
Lancet Oncol 2019;
20: e616**

Burki TK. Veliparib for advanced ovarian cancer. *Lancet Oncol* 2019; **20**: e615—In this News piece, the affiliation for Jonathan Ledermann has been corrected. This correction has been made to the online version as of Oct 30, 2019.

Published Online
September 23, 2019
[https://doi.org/10.1016/S1470-2045\(19\)30593-5](https://doi.org/10.1016/S1470-2045(19)30593-5)

Published Online
September 23, 2019
[https://doi.org/10.1016/S1470-2045\(19\)30594-7](https://doi.org/10.1016/S1470-2045(19)30594-7)